Evotec Announces Progress in Neuroscience Collaboration With Bristol Myers Squibb

Key scientific achievement advances the joint pipeline in the strategic neuroscience partnership with Bristol Myers Squibb and earns a payment of US$ 20 m to Evotec to progress further researchHAMBURG

AccesswireJun 12 13:50

EATON VANCE TAX ADVANTAGED DIVIDEND INCOME FUND To Go Ex-Dividend On June 21st, 2024 With 0.1646 USD Dividend Per Share

June 4th - $EATON VANCE TAX ADVANTAGED DIVIDEND INCOME FUND(EVT.US)$ is trading ex-dividend on June 21st, 2024. Shareholders of record on June 21st, 2024 will receive 0.1646 USD dividend per share

Futu NewsJun 4 07:45

Evotec, Inserm, Lille University Hospital and Inserm Transfert Enter Collaboration to Identify Novel Therapeutic Targets in Obesity and Metabolic Diseases

Partnership will expand Evotec's molecular patient database in the area of metabolic diseases and in particular obesityEvotec will leverage its leading PanOmics technologies for the generation of larg

AccesswireMay 30 14:00

Evotec and CHDI Foundation Extend Strategic Drug Discovery Collaboration in Huntington's Disease

Longstanding alliance between Evotec and CHDI to enable the development of therapeutics for Huntington's diseaseOne of Evotec's largest strategic drug discovery alliancesHAMBURG, GERMANY / ACCESSWIRE

AccesswireMay 28 13:50

EATON VANCE TAX ADVANTAGED DIVIDEND INCOME FUND(EVT.US) Director Buys US$6,950.37 in Common Stock

$EATON VANCE TAX ADVANTAGED DIVIDEND INCOME FUND(EVT.US)$ Director Dunn Aaron purchased 290 shares of common stock on May 17, 2024 at an average price of $23.9668 for a total value of $6,950.37.Source

Futu NewsMay 18 01:06

Evotec SE to Announce Results for First Quarter 2024 on 22 May 2024

HAMBURG, GERMANY / ACCESSWIRE / May 15, 2024 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) will announce its financial results for the first quarter of 2024

AccesswireMay 15 18:20